• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr David M. O'Malley on Identifying Which Patients Will Respond to PARP Inhibitors

Video

We're getting better at identifying which patients with ovarian cancer will respond to poly ADP-ribose polymerase (PARP) inhibitors, but we have a long way to go, said David M. O'Malley, MD, professor of medicine, Department of Gynecology, and director of Gynecologic Oncology Clinical Research at the James Cancer Center, Ohio State University.

We're getting better at identifying which patients with ovarian cancer will respond to poly ADP-ribose polymerase (PARP) inhibitors, but we have a long way to go, said David M. O'Malley, MD, professor of medicine, Department of Gynecology, and director of Gynecologic Oncology Clinical Research at the James Cancer Center, Ohio State University.

Transcript

Are we getting better at identifying which patients with ovarian cancer will respond better to PARP inhibitors?

I think we’re getting better, but we still have a long way to go. Between the BRCA testing, other HRD [homologous recombination deficiency] genes and mutations, as well as, for example, methylation of the BRCA, RAD51C and RAD51D, we’re identifying more and more patients that clearly should have PARP as a maintenance program. We will continue to identify those patients, for example, of loss of heterozygosity or the HRD positive patients that will help us separate those who we should be treating with PARP versus antivascular therapy.

In addition, with some of the ongoing phase 3 trials, we may find that combination therapy, particularly in those that are wildtype, will be our best path forward.

Related Videos
Rakendu Rajendran, MBBS
Vivek Bhalla, MD, Stanford University School of Medicine
Rayan Salih, MD, Northeast Georgia Health System
Deepak L. Bhatt, MD, MPH, MBA, FACC, FAHA, FESC, MSCAI, Mount Sinai Fuster Heart Hospital
Varsha Tanguturi, MD, MPH, Mass General Hospital
 Khush Kharidia, MD, UT Southwestern
Alexandra M. Trevino, MD, Northwestern Medicine
Andrew Kuykendall, MD, Moffitt Cancer Center
David J. Maron, MD, FASPC, Stanford University School of Medicine
Karen Vo talks about antibullying campaigns and pediatric patients with derm conditions
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.